Search results for "COMB"

showing 10 items of 7115 documents

Effects of Rapid Weight Loss on Judo Athletes: A Systematic Review

2020

Rapid weight loss (RWL) is commonly practiced among judo athletes. Although it helps them to gain the advantage over their lighter opponents, previous studies have shown that RWL can have a negative impact on the athlete’s performance and overall well-being. This systematic review aimed to synthesize the evidence that examines the influence of rapid weight loss on physiological parameters, biomarkers, and psychological well-being in judo athletes. We followed the preferred reporting items for systematic reviews and meta-analyses guidelines. We searched for studies on Web of Science and PubMed that elaborate on the influence of ≥5% RWL achieved over ≤7-day period in judokas. Out of 52 studie…

AdultMalemedicine.medical_specialtyTime Factorsmedia_common.quotation_subjectcombat sportslcsh:TX341-641Review030204 cardiovascular system & hematologyAngerAngerAthletic PerformanceOccupational safety and health03 medical and health sciencesYoung Adult0302 clinical medicineweight cuttingWeight lossWeight LossMedicineHumansCombat sportsHealth Judo athletes Martial arts Performance Psychological well-being Weight cuttingjudo athletesFatiguemedia_commonNutrition and Dieteticsbiologybusiness.industryAthletesCombat sports; Health; Judo athletes; Martial arts; Performance; Psychological well-being; Weight cuttinghealth030229 sport sciencesbiology.organism_classificationWeight Reduction ProgramsSystematic reviewFeelingmartial artsAthletesMeta-analysisPsychological well-beingPhysical therapypsychological well-beingmedicine.symptombusinessSettore M-EDF/01 - Metodi E Didattiche Delle Attivita' Motorielcsh:Nutrition. Foods and food supplyStress PsychologicalperformanceFood ScienceNutrients
researchProduct

Immediate versus delayed facilitated percutaneous coronary intervention. A pilot study

2005

The study was aimed to investigate the outcomes in patients initially successfully treated pharmacologically and immediate PCI <2 hours, and in patients initially successfully treated with pharmacological therapy and delayed PCI (12-72 hours). All patients had to have successful reperfusion, to receive the combination of a standard abciximab infusion plus half dose rtPA. Similar results were observed in both groups. Delayed PCI group showed a favorable trend in restenosis and bleedings (ns) and a significant reduced angiographic evidence of thrombus formation in IRA. Our very preliminary data suggest the safety and possible use of delayed facilitated PCI in patients with STEMI. The studied …

AdultMalemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentAbciximabMyocardial InfarctionMyocardial IschemiaEligibility DeterminationMyocardial ReperfusionPilot ProjectsAcute myocardial infarctionElectrocardiographyImmunoglobulin Fab FragmentsRestenosisInternal medicinemedicineAbciximabHumansIn patientcardiovascular diseasesThrombusAngioplasty Balloon CoronaryFacilitated pciDelayed percutaneous coronary interventionPharmacologybusiness.industryPatient SelectionPercutaneous coronary interventionAntibodies MonoclonalMiddle Agedmedicine.diseaseSurvival RateGIIb/IIIa inhibitorssurgical procedures operativeTreatment OutcomeTissue Plasminogen ActivatorConventional PCICardiologyFemaleCardiology and Cardiovascular MedicinebusinessFacilitated percutaneous coronary interventionTIMIPlatelet Aggregation InhibitorsCombined therapymedicine.drug
researchProduct

Does Hybrid Surgery Improve Quality of Life in Multilevel Cervical Degenerative Disk Disease? Five-Year Follow-up Study.

2020

Background: Patient satisfaction is becoming an increasing factor worthy of consideration when evaluating the surgical quality. The correlation between patient satisfaction and surgical outcomes 5 years after cervical hybrid surgery (HS), which incorporates anterior cervical decompression and fusion and cervical disk arthroplasty techniques in multilevel cervical degenerative disk disease, has not been evaluated. Methods: The aim of this study was firstly to analyze prospectively collected data from a sample of patients (n = 50) treated with cervical HS for selected cases of radiculopathy and myelopathy in order to evaluate pain levels of patients, using the Neck and Arm Pain scale as an ex…

AdultMalemedicine.medical_specialtyTotal Disc ReplacementVisual analogue scalemedicine.medical_treatmentDiseaseIntervertebral Disc DegenerationFunctional score03 medical and health sciencesMyelopathyAnterior cervical diskectomy fusion0302 clinical medicinePatient satisfactionPostoperative ComplicationsQuality of lifemedicineHumansRadiculopathyAgedbusiness.industryPain scaleMiddle AgedArtificial disk replacementmedicine.diseaseDecompression SurgicalArthroplastyCombined Modality TherapyMagnetic Resonance ImagingSurgerySpinal FusionTreatment OutcomePatient Satisfaction030220 oncology & carcinogenesisOrthopedic surgeryCervical VertebraeQuality of LifeSurgeryFemaleNeurology (clinical)businessDeglutition DisordersSpinal Cord CompressionHybrid surgery030217 neurology & neurosurgeryFollow-Up StudiesWorld neurosurgery
researchProduct

Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated don…

2009

Graft-versus-host disease (GVHD) is a major cause of morbidity and mortality after allogeneic haematopoietic cell transplantation from unrelated donors. Anti-T-cell globulins (ATGs) might lower the incidence of GVHD. We did a prospective, randomised, multicentre, open-label, phase 3 trial to compare standard GVHD prophylaxis with ciclosporin and methotrexate with or without anti-Jurkat ATG-Fresenius (ATG-F).Between May 26, 2003, and Feb 8, 2007, 202 patients with haematological malignancies were centrally randomly assigned using computer-generated centre-stratified block randomisation between treatment groups receiving ciclosporin and methotrexate with or without additional ATG-F. One patie…

AdultMalemedicine.medical_specialtyTransplantation ConditioningAdolescentmedicine.medical_treatmentT-LymphocytesGraft vs Host DiseaseHematopoietic stem cell transplantationGastroenterologyInternal medicinemedicineHumansTransplantation HomologousCumulative incidenceProspective StudiesAntilymphocyte Serumbusiness.industryHazard ratioHematopoietic Stem Cell TransplantationMiddle AgedCiclosporinmedicine.diseaseSurvival AnalysisAnti-thymocyte globulinSurgeryTransplantationGraft-versus-host diseaseMethotrexateOncologyHematologic NeoplasmsCyclosporineRegression AnalysisDrug Therapy CombinationFemaleTransplantation ConditioningbusinessImmunosuppressive Agentsmedicine.drugThe Lancet. Oncology
researchProduct

Two yr mycophenolate mofetil plus low-dose calcineurin inhibitor for renal dysfunction after liver transplant

2009

We assessed the efficacy and outcome of low through level of calcineurin inhibitors (CNI) and introducing mycophenolate mofetil (MMF) in liver transplant (LT) patients with CNI-related renal dysfunction. Thirty LT patients were converted to combined therapy and compared with 30 patients used as a contemporary control group receiving CNI only. The two groups were matched for sex, age, months after LT, immunosuppressive treatment, creatinine level, presence of diabetes and calculated glomerular filtration rate (GFR) via Cockroft-Gault method. After two years, in the MMF serum creatinine decreased from 1.65 mg/dL (range 1.33-3.5) to 1.4 mg/dL (range 0.9-4.7) (p = 0.002) and GFR increased from …

AdultMalemedicine.medical_specialtyUrinary systemmedicine.medical_treatmentCalcineurin InhibitorsUrologyRENAL DYSFUNCTIONRenal functionCALCINEURIN INHIBITORS; IMMUNOSUPPRESSION; LIVER TRANSPLANTATION; MYCOPHENOLATE MOFETIL; RENAL DYSFUNCTIONLiver transplantationKidney Function TestsTacrolimusMycophenolic acidNephrotoxicitychemistry.chemical_compoundmedicineHumansMYCOPHENOLATE MOFETILAgedTransplantationCreatinineIMMUNOSUPPRESSIONDose-Response Relationship Drugbusiness.industryGraft SurvivalMiddle AgedMycophenolic AcidTacrolimusLiver TransplantationCalcineurinliver transplantTreatment OutcomechemistryCreatinineImmunologyKidney Failure ChronicDrug Therapy CombinationFemalebusinessImmunosuppressive AgentsGlomerular Filtration Ratemedicine.drug
researchProduct

Systemic Treatment with Interferon-α2B: An Effective Method to Prevent Sterility after Bilateral Mumps Orchitis

1991

In men orchitis represents the most common complication of mumps infection and occurs in 5 to 37% of this population. Bilateral manifestation is observed in 16 to 65% of the patients. The most important danger is the risk of testicular atrophy which results in sterility. Four patients with bilateral mumps orchitis received systemic treatment with interferon-alpha 2B (3 x 10(6) IU per day) for 7 days. All acute symptoms of mumps orchitis disappeared within 2 to 4 days of hospitalization. During 6 to 15 months of followup no incidence of testicular atrophy was observed. In 3 of 4 patients pre-treatment examination revealed subfertility (oligoasthenospermia), while 2 to 4 months after interfer…

AdultMalemedicine.medical_specialtyUrologyPopulationAlpha interferonOrchitisInterferon alpha-2TestismedicineHumansProspective StudiesRadionuclide ImagingAdverse effecteducationMumpsInfertility MaleInterferon alfaAcetaminophenUltrasonographyeducation.field_of_studyPalpationTesticular atrophybusiness.industryInterferon-alphamedicine.diseaseRecombinant ProteinsSurgeryConcomitantDrug EvaluationOrchitisComplicationbusinessmedicine.drugJournal of Urology
researchProduct

Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data

2009

Summary Background We analysed 5-year treatment with agalsidase alfa enzyme replacement therapy in patients with Fabry's disease who were enrolled in the Fabry Outcome Survey observational database (FOS). Methods Baseline and 5-year data were available for up to 181 adults (126 men) in FOS. Serial data for cardiac mass and function, renal function, pain, and quality of life were assessed. Safety and sensitivity analyses were done in patients with baseline and at least one relevant follow-up measurement during the 5 years (n=555 and n=475, respectively). Findings In patients with baseline cardiac hypertrophy, treatment resulted in a sustained reduction in left ventricular mass (LVM) index af…

AdultMalemedicine.medical_specialtyUrologyRenal functionKidney Function TestsMuscle hypertrophyQuality of lifeSurveys and QuestionnairesEpidemiologymedicineHumansRegistriesPain MeasurementVascular diseasebusiness.industryGeneral MedicineEnzyme replacement therapymedicine.diseaseFabry's diseaseFabry diseaseRecombinant ProteinsSurgeryIsoenzymesTreatment Outcomealpha-GalactosidaseHeart Function TestsQuality of LifeFabry DiseaseFemalebusinessThe Lancet
researchProduct

The clinical use of statistical permutation test methodology: a tool for identifying predictive variables of outcome.

2015

&lt;b&gt;&lt;i&gt;Objectives:&lt;/i&gt;&lt;/b&gt; To identify the predictive variables affecting the outcome after radical surgery for bladder cancer by a newer statistical methodology, i.e. nonparametric combination (NPC). &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; A multicenter study enrolled 1,312 patients who had undergone radical cystectomy for bladder cancer in 11 Italian oncological centers from January 1982 to December 2002. A statistical analysis&lt;b&gt; &lt;/b&gt;of their medical history and diagnostic, pathological and postoperative variables was performed using a NPC test. The&lt;b&gt; &lt;/b&gt;patients were included in a comprehensive database with medical history and cli…

AdultMalemedicine.medical_specialtyUrologyStatistics as TopicHydronephrosisnonparametric combinationCystectomyOutcome (game theory)Statistics NonparametricBladder cancer; Permutation test; PrognosisSettore MED/24 - UrologiaBladder cancer Prognosis Permutation testPredictive Value of TestsResamplingMedicineHumansPermutation testRadical surgeryIntensive care medicineAgedNeoplasm StagingRetrospective StudiesAged 80 and overCarcinoma Transitional CellBladder cancerbusiness.industryBladder cancerProstatePermutation testsMiddle Agedmedicine.diseasePrognosisradical surgery for bladder; nonparametric combinationradical surgery for bladderSurgeryPatient Outcome Assessmentbladder cancer; Prognosis; Permutation testsItalyUrinary Bladder NeoplasmsBladdder Cancer Cystectomy outcome statistical methodologyData Interpretation StatisticalLymphatic MetastasisMultivariate AnalysisFemalePredictive variablesradical surgery for bladder nonparametric combinationbusiness
researchProduct

Radical cystectomy with or without adjuvant polychemotherapy for non-organ-confined transitional cell carcinoma of the urinary bladder: prognostic im…

1996

To analyze the effectiveness of adjuvant polychemotherapy after radical cystectomy for non-organ-confined transitional cell bladder cancer (Stages pT3b, pT4a, and/or pN1 or pN2).Of 166 consecutive patients undergoing cystectomy at two institutions from 1987 to 1993, 80 received adjuvant polychemotherapy with methotrexate, vinblastine, and cisplatin plus doxorubicin (MVAC) or epirubicin (MVEC), whereas 86 had cystectomy only. The patients were evaluated for relapse-free survival and length of progression-free interval on the basis of follow-up data obtained in 1995 and 1996.Kaplan-Meier analysis revealed a significantly higher progression-free rate for patients after adjuvant chemotherapy (P…

AdultMalemedicine.medical_specialtyUrologymedicine.medical_treatmentUrologyCystectomyDisease-Free SurvivalCystectomyAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansProspective StudiesProspective cohort studyLymph nodeAgedAged 80 and overChemotherapyCarcinoma Transitional CellUrinary bladderbusiness.industryMiddle Agedmedicine.diseasePrognosisSurgerymedicine.anatomical_structureTransitional cell carcinomaUrinary Bladder NeoplasmsChemotherapy AdjuvantLymphatic MetastasisDisease ProgressionFemalebusinessAdjuvantFollow-Up StudiesUrology
researchProduct

Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study…

1995

A total of 83 patients with nonorgan-confined bladder cancer with or without lymph node metastases (tumor stages pT3b, pT4a and/or pN1, pN2) was evaluated in November 1993 for relapse-free and overall survival. All patients underwent radical cystectomy between 1987 and 1991, 38 underwent adjuvant polychemotherapy with methotrexate, vinblastine and cisplatin plus doxorubicin (M-VAC) or epirubicin (M-VEC). Of the 83 patients 49 had entered a prospective randomized trial comparing adjuvant to no adjuvant treatment. The protocol was activated in May 1987. Patient recruitment was concluded in December 1990 because an interim analysis of the 49 randomized patients revealed a significant prognosti…

AdultMalemedicine.medical_specialtyUrologymedicine.medical_treatmentUrologyCystectomyVinblastinelaw.inventionCystectomyRandomized controlled triallawAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesSurvival rateAgedEpirubicinCarcinoma Transitional CellUrinary bladderBladder cancerbusiness.industryMiddle AgedInterim analysismedicine.diseaseCombined Modality TherapyVinblastineSurgerySurvival Ratemedicine.anatomical_structureMethotrexateUrinary Bladder NeoplasmsChemotherapy AdjuvantDoxorubicinLymphatic MetastasisFemaleCisplatinbusinessmedicine.drugEpirubicinThe Journal of urology
researchProduct